• Citer

Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial.

par Kenemans, Peter;Bundred, Nigel J;Foidart, Jean-Michel;Kubista, Ernst;von Schoultz, Bo;Sismondi, Piero;Vassilopoulou-Sellin, Rena;Yip, Cheng Har;Egberts, Jan;Mol-Arts, Mirjam;Mulder, Roel;van Os, Bertil;Beckmann, Matthias W;Simon, Philippe
Référence Lancet oncology, 10, 2, page (135-146)
Publication Publié, 2009-02

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial.
Auteur:	Kenemans, Peter; Bundred, Nigel J; Foidart, Jean-Michel; Kubista, Ernst; von Schoultz, Bo; Sismondi, Piero; Vassilopoulou-Sellin, Rena; Yip, Cheng Har; Egberts, Jan; Mol-Arts, Mirjam; Mulder, Roel; van Os, Bertil; Beckmann, Matthias W; Simon, Philippe
Informations sur la publication:	Lancet oncology, 10, 2, page (135-146)
Statut de publication:	Publié, 2009-02
Sujet CREF:	Sciences bio-médicales et agricoles
MeSH keywords:	Adult
	Aged
	Antineoplastic Agents, Hormonal -- adverse effects
	Breast Neoplasms -- chemically induced -- pathology
	Double-Blind Method
	Estrogen Replacement Therapy -- adverse effects
	Female
	Hot Flashes -- drug therapy
	Humans
	Middle Aged
	Neoplasm Recurrence, Local -- chemically induced -- pathology
	Norpregnenes -- adverse effects
	Osteoporosis, Postmenopausal -- prevention & control
	Vasomotor System -- drug effects
Note générale:	Journal Article
	Multicenter Study
	Randomized Controlled Trial
	Research Support, Non-U.S. Gov't
Langue:	Anglais
Identificateurs:	urn:issn:1470-2045
	info:doi/10.1016/S1470-2045(08)70341-3
	info:pii/S1470-2045(08)70341-3
	info:pmid/19167925